Dr. Luc Truyen, MD, PhD, was trained as a neurologist in Belgium and the Netherlands and received his doctorate in Medical Sciences from the University of Antwerp. After a career in academia with special interest in multiple sclerosis, stroke and neuro-degenerative disease, he joined Janssen Research Foundation (JNJ) in 1998. He was part of the team that developed Reminyl/Razadyne™ for the symptomatic treatment of AD in early 2000’s. After that, he has had roles of increasing responsibilities and scope within JNJ, from leading compound development teams to large functional groups like Global Clinical Operations and later Clinical Development Operations of the Janssen R&D for several years. In 2011, Luc joined Janssen Alzheimer Immunotherapy LLC. After serving as its Chief Medical Officer and Head of Research & Development, he joined the Office of the Chief Medical Officer of JNJ as Head Clinical Innovation early 2013. In recognition of the increasing sense of urgency and required focus on Alzheimer’s Disease, Luc was named Vice President of Neuroscience External Affairs and Chair, Johnson&Johnson, Global Fight against Alzheimer’s Disease in April 2014. In this role, Luc coordinates all efforts for JNJ in the external environment related to Alzheimer’s disease.